<DOC>
	<DOCNO>NCT02379910</DOCNO>
	<brief_summary>This study safety , tolerability , pharmacokinetics pharmacodynamics AM1030-CREAM patient Atopic Dermatitis .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , PK PD AM1030-CREAM Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Males and/or female ethnic origin 18 65 year age Body mass index 18.0 35.0 kg/m2 Subjects AD define Hanifen Rajka criterion mild severe disease activity ( IGA 24 ) AD lesion amenable cutaneous treatment locate trunk and/or limbs Subjects scar , mole , tattoo , sunburn blemish test area Systemic treatment immunosuppressant , immunomodulators corticosteroids within 2 week prior dose Topical treatment corticosteroid , antibiotic and/or immunomodulators within 4 day prior dose Treatment systemic antihistamine within 24 hour first dose administration Treatment SSRIs within 2 week first dose administration Subjects receive phototherapy within 4 week prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>